Nxera Pharma Co., Ltd.
As of September 3, 2026: Report on milestone receipt related to the late-stage milestone achievement of Centessa Pharmaceuticals Limited’s OX2R agonist
Nexera Pharma has achieved the late-stage development milestone for Centessa's OX2R agonist and will receive 8.6 million USD. Revenue recognition is planned for the third quarter of the fiscal year ending December 2026.
Key Figures
- Milestone receipt amount: 8.6百万米ドル
- Timing of revenue recognition: 2026年12月期第3四半期
- Currency conversion rate: 1USD=160.25円（注記の換算値）
AI要約
Overview of performance
Today, as Centessa Pharmaceuticals Limited achieved a milestone for the late-stage development of the OX2R agonist, Nexera Pharma will receive 8.6 million USD. The full amount is expected to be recognized as revenue in the third quarter of the fiscal year ending December 2026. Even after the acquisition of Centessa, the company retains milestones and royalties related to future development and commercialization.
Outlook and key points
The acquisition of Centessa by Lilly emphasizes that the OX2R program's development and commercialization progress continues. It is already incorporated into the initial earnings forecast at the start of 2026, and further milestone achievements are anticipated.
Nxera Pharma Co., Ltd.
Company overview · Stock price · Financial data · All IR
